MedPath

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Phase 2
Completed
Conditions
Obesity
Interventions
First Posted Date
2014-09-17
Last Posted Date
2016-10-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
335
Registration Number
NCT02243202

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Phase 1
Terminated
Conditions
Asthma
Healthy
Interventions
Drug: Placebo
Drug: Nasal Allergen Challenge
First Posted Date
2014-09-17
Last Posted Date
2016-03-23
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
17
Registration Number
NCT02243189

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-42756493 Tablet
Drug: JNJ-42756493 Capsule
First Posted Date
2014-09-04
Last Posted Date
2014-12-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT02231489

Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Completed
Conditions
Prostatic Neoplasms
Interventions
Other: No Intervention
First Posted Date
2014-09-03
Last Posted Date
2014-09-25
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
382
Registration Number
NCT02230059

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

First Posted Date
2014-09-03
Last Posted Date
2016-01-20
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
102
Registration Number
NCT02230046

Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo (Matched to Esketamine)
Drug: Placebo (Matched to Mirtazapine)
First Posted Date
2014-08-28
Last Posted Date
2014-12-30
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
26
Registration Number
NCT02228239

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

Early Phase 1
Completed
Conditions
Healthy
First Posted Date
2014-08-20
Last Posted Date
2014-09-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
16
Registration Number
NCT02221726
© Copyright 2025. All Rights Reserved by MedPath